Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Colorectal Neoplasms

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 75 articles: HTML format Text format

Single Articles

May 2018
1. APARICIO T, Ducreux M, Faroux R, Barbier E, et al
   Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
   Eur J Cancer. 2018;98:1-9.
   PubMed     Text format     Abstract available
   
   
   
2. APARICIO T, Bouche O, Francois E, Retornaz F, et al
   Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
   Eur J Cancer. 2018;97:16-24.
   PubMed     Text format     Abstract available
   
   
   
3. AUCLIN E, Andre T, Taieb J, Benetkiewicz M, et al
   Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.
   Eur J Cancer. 2018 May 3. pii: S0959-8049(18)30782.
   PubMed     Text format    
   
   
   
4. GOEY KKH, Mahmoud R, Sorbye H, Glimelius B, et al
   Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
   Eur J Cancer. 2018;96:115-124.
   PubMed     Text format     Abstract available
   
   
   April 2018
5. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
   A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
   Eur J Cancer. 2018;96:105-110.
   PubMed     Text format     Abstract available
   
   
   
6. MATSUDA C, Ishiguro M, Teramukai S, Kajiwara Y, et al
   A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
   Eur J Cancer. 2018;96:54-63.
   PubMed     Text format     Abstract available
   
   
   March 2018
7. TACHON G, Frouin E, Karayan-Tapon L, Auriault ML, et al
   Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
   Eur J Cancer. 2018 Mar 5. pii: S0959-8049(18)30121.
   PubMed     Text format    
   
   
   
8. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
   Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.
   Eur J Cancer. 2018;94:1-5.
   PubMed     Text format     Abstract available
   
   
   February 2018
9. YOSHINO T, Hsu Y, Nasroulah F
   Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
   Eur J Cancer. 2018 Feb 9. pii: S0959-8049(18)30084.
   PubMed     Text format    
   
   
   
10. ZOU D, Lou J, Ke J, Mei S, et al
    Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression.
    Eur J Cancer. 2018;93:1-9.
    PubMed     Text format     Abstract available
    
    
    January 2018
11. VAN ROOIJEN KL, Shi Q, Goey KKH, Meyers J, et al
    Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    Eur J Cancer. 2018;91:99-106.
    PubMed     Text format     Abstract available
    
    
    
12. IBRAHIM S, Raoul W, Lecomte T, Paintaud G, et al
    Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31461.
    PubMed     Text format    
    
    
    December 2017
13. VAN CUTSEM E, Mayer RJ, Laurent S, Winkler R, et al
    The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Eur J Cancer. 2017;90:63-72.
    PubMed     Text format     Abstract available
    
    
    November 2017
14. MODEST DP, Denecke T, Pratschke J, Ricard I, et al
    Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Eur J Cancer. 2017;88:77-86.
    PubMed     Text format     Abstract available
    
    
    
15. COHEN R, Buhard O, Cervera P, Hain E, et al
    Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Eur J Cancer. 2017;86:266-274.
    PubMed     Text format     Abstract available
    
    
    October 2017
16. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Eur J Cancer. 2017;86:197-206.
    PubMed     Text format     Abstract available
    
    
    
17. KEIKES L, Koopman M, Tanis PJ, Lemmens VEPP, et al
    Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.
    Eur J Cancer. 2017;86:166-177.
    PubMed     Text format     Abstract available
    
    
    
18. PREVOSTEL C, Blache P
    The dose-dependent effect of SOX9 and its incidence in colorectal cancer.
    Eur J Cancer. 2017;86:150-157.
    PubMed     Text format     Abstract available
    
    
    
19. MALKA D, Rotolo F, Boige V
    First-line treatment in metastatic colorectal cancer: Important or crucial?
    Eur J Cancer. 2017;84:363-366.
    PubMed     Text format    
    
    
    September 2017
20. TURATI F, Bravi F, Di Maso M, Bosetti C, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk.
    Eur J Cancer. 2017;85:86-94.
    PubMed     Text format     Abstract available
    
    
    August 2017
21. MODEST DP, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
    Eur J Cancer. 2017;84:262-269.
    PubMed     Text format     Abstract available
    
    
    
22. MAY-WILSON S, Sud A, Law PJ, Palin K, et al
    Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
    Eur J Cancer. 2017;84:228-238.
    PubMed     Text format     Abstract available
    
    
    
23. STINTZING S, Tejpar S, Gibbs P, Thiebach L, et al
    Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.
    Eur J Cancer. 2017;84:69-80.
    PubMed     Text format     Abstract available
    
    
    
24. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed     Text format    
    
    
    July 2017
25. TOPI G, Ehrnstrom R, Jirstrom K, Palmquist I, et al
    Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer.
    Eur J Cancer. 2017;83:279-289.
    PubMed     Text format     Abstract available
    
    
    
26. CASCINU S, Rosati G, Nasti G, Lonardi S, et al
    Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase
    Eur J Cancer. 2017;83:106-115.
    PubMed     Text format     Abstract available
    
    
    
27. KATONA BW, Yang YX
    Colorectal cancer risk associated with the CHEK2 1100delC variant.
    Eur J Cancer. 2017;83:103-105.
    PubMed     Text format    
    
    
    
28. STINTZING S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, et al
    Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Eur J Cancer. 2017;79:50-60.
    PubMed     Text format     Abstract available
    
    
    June 2017
29. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;82:92-102.
    PubMed     Text format     Abstract available
    
    
    
30. EMILE JF, Julie C, Le Malicot K, Lepage C, et al
    Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Eur J Cancer. 2017;82:16-24.
    PubMed     Text format     Abstract available
    
    
    
31. CARRATO A, Abad A, Massuti B, Gravalos C, et al
    First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Eur J Cancer. 2017;81:191-202.
    PubMed     Text format     Abstract available
    
    
    
32. YAMANO T, Yamauchi S, Kimura K, Babaya A, et al
    Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.
    Eur J Cancer. 2017;81:90-101.
    PubMed     Text format     Abstract available
    
    
    
33. THOMSEN M, Guren MG, Skovlund E, Glimelius B, et al
    Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
    Eur J Cancer. 2017;81:26-35.
    PubMed     Text format     Abstract available
    
    
    
34. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    PubMed     Text format     Abstract available
    
    
    
35. YOSHINO T, Obermannova R, Bodoky G, Garcia-Carbonero R, et al
    Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Eur J Cancer. 2017;78:61-69.
    PubMed     Text format     Abstract available
    
    
    
36. ADAM R, Yi B, Innominato PF, Barroso E, et al
    Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
    Eur J Cancer. 2017;78:7-15.
    PubMed     Text format     Abstract available
    
    
    April 2017
37. ROVERS KP, Simkens GA, Vissers PA, Lemmens VE, et al
    Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.
    Eur J Cancer. 2017;75:132-140.
    PubMed     Text format     Abstract available
    
    
    March 2017
38. FROUWS MA, Rademaker E, Bastiaannet E, van Herk-Sukel MP, et al
    The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
    Eur J Cancer. 2017;77:24-30.
    PubMed     Text format     Abstract available
    
    
    
39. BERGER MD, Yamauchi S, Cao S, Hanna DL, et al
    Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Eur J Cancer. 2017;77:13-20.
    PubMed     Text format     Abstract available
    
    
    
40. HOLCH JW, Heinemann V
    Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients.
    Eur J Cancer. 2017;77:1-2.
    PubMed     Text format    
    
    
    
41. KWAKMAN JJ, Simkens LH, Mol L, Kok WE, et al
    Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Eur J Cancer. 2017;76:93-99.
    PubMed     Text format     Abstract available
    
    
    
42. DEL RIO M, Mollevi C, Bibeau F, Vie N, et al
    Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    Eur J Cancer. 2017;76:68-75.
    PubMed     Text format     Abstract available
    
    
    
43. TREASURE T, Williams NR
    Best available evidence related to clinical benefit of surgical resection in multimodality treatment of metastatic colorectal cancer indicates that a randomised controlled trial is warranted.
    Eur J Cancer. 2017;75:310-312.
    PubMed     Text format    
    
    
    February 2017
44. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    PubMed     Text format     Abstract available
    
    
    
45. FRANKEN MD, van Rooijen EM, May AM, Koffijberg H, et al
    Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Eur J Cancer. 2017;75:204-212.
    PubMed     Text format     Abstract available
    
    
    
46. HUGEN N, Nagtegaal ID
    Distinct metastatic patterns in colorectal cancer patients based on primary tumour location.
    Eur J Cancer. 2017;75:3-4.
    PubMed     Text format    
    
    
    
47. PAPAMICHAEL D, Aapro M
    Geriatric factors and outcomes in metastatic colorectal cancer.
    Eur J Cancer. 2017 Feb 10. pii: S0959-8049(16)32566.
    PubMed     Text format    
    
    
    
48. MECHERA R, Schuster T, Rosenberg R, Speich B, et al
    Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;72:84-94.
    PubMed     Text format     Abstract available
    
    
    
49. SCHAFFAR R, Rachet B, Belot A, Woods LM, et al
    Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.
    Eur J Cancer. 2017;72:78-83.
    PubMed     Text format     Abstract available
    
    
    
50. FRIN AC, Evesque L, Gal J, Benezery K, et al
    Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.
    Eur J Cancer. 2017;72:124-136.
    PubMed     Text format     Abstract available
    
    
    January 2017
51. MODEST DP, Neumann UP, Pratschke J
    FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Eur J Cancer. 2017 Jan 9. pii: S0959-8049(16)33085.
    PubMed     Text format    
    
    
    
52. SARTORE-BIANCHI A, Pietrantonio F, Amatu A, Milione M, et al
    Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Eur J Cancer. 2017;71:43-50.
    PubMed     Text format     Abstract available
    
    
    
53. 'T LAM-BOER J, van der Stok EP, Huiskens J, Verhoeven RH, et al
    Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands.
    Eur J Cancer. 2017;71:109-116.
    PubMed     Text format     Abstract available
    
    
    
54. CHAN AK, Siriwardena AK
    Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer.
    Eur J Cancer. 2017;71:51-52.
    PubMed     Text format    
    
    
    December 2016
55. CREMOLINI C, Casagrande M, Loupakis F, Aprile G, et al
    Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Eur J Cancer. 2016 Dec 13. pii: S0959-8049(16)32534.
    PubMed     Text format     Abstract available
    
    
    November 2016
56. HOLCH JW, Ricard I, Stintzing S, Modest DP, et al
    The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Eur J Cancer. 2016;70:87-98.
    PubMed     Text format     Abstract available
    
    
    
57. DUCREUX M, Pignon JP
    Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?
    Eur J Cancer. 2016;69:178-179.
    PubMed     Text format    
    
    
    
58. APARICIO T, Gargot D, Teillet L, Maillard E, et al
    Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Eur J Cancer. 2016 Nov 5. pii: S0959-8049(16)32475.
    PubMed     Text format     Abstract available
    
    
    
59. ROTTENBERG Y, Ratzon NZ, Cohen M, Hubert A, et al
    Unemployment risk at 2 and 4 years following colorectal cancer diagnosis: a population based study.
    Eur J Cancer. 2016;69:70-76.
    PubMed     Text format     Abstract available
    
    
    
60. GOEY KK, 't Lam-Boer J, de Wilt JH, Punt CJ, et al
    Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
    Eur J Cancer. 2016;69:166-177.
    PubMed     Text format     Abstract available
    
    
    October 2016
61. BOUCHAHDA M, Boige V, Smith D, Karaboue A, et al
    Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Eur J Cancer. 2016;68:163-172.
    PubMed     Text format     Abstract available
    
    
    
62. PRICE T, Kim TW, Li J, Cascinu S, et al
    Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Eur J Cancer. 2016;68:51-59.
    PubMed     Text format     Abstract available
    
    
    
63. ZHAO Y, Fan D, Ru B, Cheng KW, et al
    6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Eur J Cancer. 2016;68:38-50.
    PubMed     Text format     Abstract available
    
    
    September 2016
64. HEINEMANN V, Rivera F, O'Neil BH, Stintzing S, et al
    A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2016;67:11-20.
    PubMed     Text format     Abstract available
    
    
    August 2016
65. MOL L, Ottevanger PB, Koopman M, Punt CJ, et al
    The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
    Eur J Cancer. 2016;66:138-143.
    PubMed     Text format     Abstract available
    
    
    July 2016
66. CABALLERO-BANOS M, Benitez-Ribas D, Tabera J, Varea S, et al
    Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
    Eur J Cancer. 2016;64:167-174.
    PubMed     Text format     Abstract available
    
    
    June 2016
67. BREUGOM AJ, Bastiaannet E, Boelens PG, Iversen LH, et al
    Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.
    Eur J Cancer. 2016;63:110-117.
    PubMed     Text format     Abstract available
    
    
    May 2016
68. BANDO H, Doi T, Muro K, Yasui H, et al
    A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Eur J Cancer. 2016;62:46-53.
    PubMed     Text format     Abstract available
    
    
    
69. LOGANADANE G, Servagi-Vernat S, Schernberg A, Schlienger M, et al
    Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series.
    Eur J Cancer. 2016;58:83-9.
    PubMed     Text format     Abstract available
    
    
    March 2016
70. MCLACHLAN SA, Fisher RJ, Zalcberg J, Solomon M, et al
    The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).
    Eur J Cancer. 2016;55:15-26.
    PubMed     Text format     Abstract available
    
    
    
71. HAAGENSEN EJ, Thomas HD, Mudd C, Tsonou E, et al
    Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Eur J Cancer. 2016;56:69-76.
    PubMed     Text format     Abstract available
    
    
    January 2016
72. HELDER-WOOLDERINK JM, Blok EA, Vasen HF, Hollema H, et al
    Ovarian cancer in Lynch syndrome; a systematic review.
    Eur J Cancer. 2016;55:65-73.
    PubMed     Text format     Abstract available
    
    
    
73. FORMICA V, Formica D, Formica G
    The 'death pace' in the CO.17 trial.
    Eur J Cancer. 2016;53:1-4.
    PubMed     Text format     Abstract available
    
    
    
74. CASHIN PH, Mahteme H, Spang N, Syk I, et al
    Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    Eur J Cancer. 2016;53:155-62.
    PubMed     Text format     Abstract available
    
    
    
75. NOREN A, Eriksson HG, Olsson LI
    Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study.
    Eur J Cancer. 2016;53:105-14.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: